TABLE 14-1 Relevant Data Identified for Flavonoids


Type of Injury/Insult

Type of Study and Subjects



Tier 1: Clinical trials

Cao et al., 2008

Acute cerebral infarction

Meta-analysis of 9 randomized and quasi-randomized controlled clinical trials

Dengzhanhua (Erigeron breviscapus) alone or as supplement to another treatment vs. placebo or no treatment

None of the outcome measures of this meta-analysis (death from any cause at the end of follow-up period, death or dependence at the end of follow-up period, quality of life, and adverse events) were included in any of the selected trials. However, post hoc analysis showed that, compared to controls, patients taking dengzhanhua were more likely to have at least 45% improvement in neurologic condition (RRb=1.53, 95% CIc: 1.36–1.72). Study heterogeneity was 0%.

na=723 male and female patients

Chan et al., 2008

Brachial flow-mediated dilatation

Randomized, double-blind, placebo-controlled

Postinjury, isoflavone supplement (80 mg/day) or placebo for 12 weeks

Compared with controls, isoflavone-treated patients had greater flow-mediated dilatation (FMD; 1.2% vs. −0.1%, p=0.035) and lower prevalence of impaired FMD (58% vs. 79%, p=0.023) at 12 weeks. Adjusted for baseline differences in FMD, isoflavone treatment was found to be associated with lower prevalence of FMD impairment (ORd=0.32, 95% CI: 0.13–0.80; p=0.014). Treatment effect on brachial FMD was inversely related to baseline FMD (re=−0.514, p < 0.001).


Isoflavone treatment had greater effect on current or past smokers than non-smokers (p=0.045) and on non-diabetics than diabetics (p=0.030). Moreover, isoflavone treatment for 12 weeks lowered high sensitivity-C-reactive protein level (treatment effect =−1.7%, 95% CI: −3.3 to −0.1%; p=0.033

There was no significant effect on nitroglycerin-mediated dilatation, blood pressure, heart rate, serum levels of fasting glucose and insulin, hemoglobin A1c, or oxidative stress.

No significant adverse effects from the isoflavone treatment were mentioned.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement